Acrx stock forecast.

CynergisTek, Inc. (NYSEAMERICAN:CTEK) issued its quarterly earnings results on Thursday, November, 11th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.22. The company had revenue of $3.83 million for the quarter.AcelRx Pharmaceuticals, Inc. (ACRX) stock forecast and price target. Find the latest AcelRx Pharmaceuticals, Inc. ACRX analyst stock forecast, price target, and recommendation trends with in-depth ...377.43. -0.11%. 9.38M. View today's AcelRx Pharmaceuticals Inc stock price and latest ACRX news and analysis. Create real-time notifications to follow any changes in the live stock price.AcelRx Pharmaceuticals last issued its earnings data on November 8th, 2023. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The company earned $0.12 million during the quarter. AcelRx Pharmaceuticals has generated ($2.23) earnings per share over the last year ...

According to 2 stock analysts, the average 12-month stock price forecast for ACRX stock stock is $4.63, which predicts an increase of 623.55%. The lowest target is $4.25 and the highest is $5.00. On average, analysts rate ACRX stock stock as a strong buy. Analyst Consensus: Strong Buy * Price targets were last updated on Oct 2, 2023.

Dec 1, 2023 · Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for ACRX stock stock is $4.63, which predicts an increase of 623.55%. The lowest target is $4.25 and the highest is $5.00. On average, analysts rate ACRX stock stock as a strong buy. Oct 25, 2022 · The reverse stock split will become effective at 5:01 p.m. ET on Tuesday, October 25, 2022. AcelRx's common stock will continue to be traded on the Nasdaq Global Market under the symbol ACRX and ...

The reverse stock split will become effective at 5:01 p.m. ET on Tuesday, October 25, 2022. AcelRx's common stock will continue to be traded on the Nasdaq Global Market under the symbol ACRX and ...Stock Price Forecast The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00.ACRX Analyst Estimates Stock Screener Earnings Calendar Sectors Nasdaq | ACRX U.S.: Nasdaq AcelRx Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours …Stock Price Forecast. The 2 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.63, with a high estimate of 5.00 and a low estimate of 4.25. The ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Find the latest AcelRx Pharmaceuticals, Inc. (ACRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

ACRX Analyst Estimates Stock Screener Earnings Calendar Sectors Nasdaq | ACRX U.S.: Nasdaq AcelRx Pharmaceuticals Inc. Watch list After Hours Last Updated: Sep 8, 2023 7:09 p.m. EDT Delayed...

AcelRx Pharmaceuticals, Inc. 05 Apr, 2023, 08:30 ET. In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant. AcelRx announces full ...Earnings announcement* for ACRX: May 15, 2023. AcelRx Pharmaceuticals, Inc. is estimated to report earnings on 05/15/2023. The upcoming earnings date is derived from an algorithm based on a ...Forecst.com predicts future values using technical analysis of a large number of analytical parameters. ACV stock returns are also predicted based on historical data. According to our research, ACV stock is a bad long-term investment. ACV share price has been in a bull cycle for the past year.Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Marker Therapeutics Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The ...Find real-time VRNA - Verona Pharma PLC stock quotes, company profile, news and forecasts from CNN Business.

ACRX Stock Forecast. While there’s much to be desired from the market after this year, analysts remain bullish. Most recently, Cantor Fitzgerald adjusted its rating to $4 but maintained an Overweight rating. Based on current trading levels, that target sits 615% higher right now.Based on 7 Wall Street analysts offering 12 month price targets for Applied Digital Corporation in the last 3 months. The average price target is $15.25 with a high forecast of $19.00 and a low forecast of $12.00. Earnings announcement* for ACRX: May 15, 2023. AcelRx Pharmaceuticals, Inc. is estimated to report earnings on 05/15/2023. The upcoming earnings date is derived from an algorithm based on a ...1.49%. $75.35M. Cara Therapeutics Inc. 13.45%. $73M. ACRX | Complete AcelRx Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.From AI system, total return is 2366.52% from 4098 forecasts. See more long term and short term forecasts for your favorite stock.About CohBar Stock (NASDAQ:CWBR) CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; …

Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients. Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise ...

Find the latest Femasys Inc. (FEMY) stock quote, history, news and other vital information to help you with your stock trading and investing.Get the latest Citius Pharmaceuticals Inc (CTXR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Baudax Bio Stock Forecast and Price Target. ... ACRX Stock Forecast: AcelRx Pharmaceuticals Buy 6 $0.69 Buy/Sell: $4.25 571.01% Baudax Bio Revenue Forecast for 2023 - 2025 - 2030. In the last two years, Baudax Bio's Revenue has grown, increasing from $490.00k to $1.27M – a growth of 159.18%.Planning a trip can be an exciting but challenging task. From booking accommodations to creating an itinerary, there are countless details to consider. One crucial aspect that should never be overlooked is checking the 7-day weather forecas...Find out why ACRX stock is a Hold. AcelRx Pharmaceuticals raised capital in December 2022, ... Management outlook to 2023 provided at the March 30, 2023 Earnings Call for fiscal 2022.AcelRx Pharmaceuticals Stock (NASDAQ: ACRX) stock price, news, charts, stock research, profile. ... Here Are 10 Other Analyst Forecasts For Monday. Lisa Levin - Sep 25, 2023, 8:39AM.Here are three reasons Aurora Cannabis stock may finally be a buy. Image source: Getty Images. 1. Cost-cutting and restructuring. Aurora Cannabis has been implementing a comprehensive plan to ...AcelRx Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ACRX updated stock price target summary.

Find real-time GNPX - Genprex Inc stock quotes, company profile, news and forecasts from CNN Business.

Dec 1, 2023 · AcelRx Pharmaceuticals last issued its earnings data on November 8th, 2023. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The company earned $0.12 million during the quarter. AcelRx Pharmaceuticals has generated ($2.23) earnings per share over the last year ...

Aug 18, 2022 · However, since the final approval in late 2018 sales have lagged any management forecast by orders of magnitude. ... clarifying that ACRX stock will be delisted if, very informally, the stock ... Acasti Pharma Inc. (ACST) share price prediction for 2023, 2024, 2025, 2026 and 2027. ACST one year forecast. Acasti Pharma stock monthly and weekly forecasts.Analyst Forecast. According to 3 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is $29.67, which is an increase of 3.16% from the latest price.ACRX Analyst Estimates Stock Screener Earnings Calendar Sectors Nasdaq | ACRX U.S.: Nasdaq AcelRx Pharmaceuticals Inc. Watch list After Hours Last Updated: Sep 8, 2023 7:09 p.m. EDT Delayed...Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ... $4.63 ( 571.11% upside) Analyst Consensus: Strong Buy Stock Forecasts News All Videos Press Releases Conversation AcelRx Reports Third Quarter 2023 …ACRX Stock Forecast. While there’s much to be desired from the market after this year, analysts remain bullish. Most recently, Cantor Fitzgerald adjusted its rating to $4 but maintained an Overweight rating. Based on current trading levels, that target sits 615% higher right now.Stock Price Forecast The 2 analysts offering 12-month price forecasts for Acurx Pharmaceuticals Inc have a median target of 11.50, with a high estimate of 13.00 and a low estimate of 10.00. We are talking returns of at least 300% over the next 12 months, according to the analysts.AcelRx Pharmaceuticals (ACRX)Opioids have made headlines in recent years, and for all the wrong reasons ...Shares used in computing net income (loss) per share of common stock, diluted. 10,924. 7,360. 10,909. 7,321 (1) Includes the following non-cash stock-based compensation expense: Research and ...AcelRx Pharmaceuticals is forecast to grow earnings and revenue by 11.4% and 63.5% per annum respectively while EPS is expected to grow by 33.4% per annum.May 9, 2023 · ACRX competes with other companies such as ATXI, PTIX, and PBLA. On May 9, 2023, ATXI stock remained unchanged, while PTIX stock increased by 2.06%. In contrast, PBLA stock decreased by 21.71%. ACRX is set to report its next earnings on May 11, 2023. ACRX operates in the health technology sector and is involved in the major pharmaceuticals ...

Stock Price Forecast. The 2 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.63, with a high estimate of 5.00 and a low estimate of 4.25. The ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Shares used in computing net income (loss) per share of common stock, diluted. 10,924. 7,360. 10,909. 7,321 (1) Includes the following non-cash stock-based compensation expense: Research and ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Inpixon have a median target of 586,488.00, with a high estimate of 586,488.00 and a low estimate of 586,488.00. The ...Instagram:https://instagram. best mortgage lenders in new mexicogoat stockkhov stockthermon group holdings Find the latest Energizer Holdings, Inc. (ENR) stock quote, history, news and other vital information to help you with your stock trading and investing. chico's fas stockbig wealth management firms AcelRx Pharmaceuticals (ACRX) Stock Forecast & Price Prediction. Estimation of the future price movement of AcelRx Pharmaceuticals stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.ACRX Analyst Estimates Stock Screener Earnings Calendar Sectors Nasdaq | ACRX U.S.: Nasdaq AcelRx Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours … alnylam pharmaceuticals inc. Stock Price Forecast. The 12 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 31.00, with a high estimate of 31.26 and a low estimate of 19.00. The median ... Here are three reasons Aurora Cannabis stock may finally be a buy. Image source: Getty Images. 1. Cost-cutting and restructuring. Aurora Cannabis has been implementing a comprehensive plan to ...